Tazeen Ahmad
Stock Analyst at B of A Securities
(2.57)
# 1,058
Out of 4,479 analysts
135
Total ratings
48.21%
Success rate
-0.26%
Average return
Main Sectors:
40 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRUS Merus | Maintains: Buy | $76 | $54.45 | +39.58% | 4 | Jun 25, 2024 | |
| ARGX argenx SE | Reiterates: Buy | $535 → $607 | $434.22 | +39.79% | 3 | Jun 24, 2024 | |
| PTCT PTC Therapeutics | Maintains: Underperform | $25 → $32 | $31.17 | +2.66% | 10 | Jun 21, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $166 → $213 | $156.75 | +35.89% | 21 | Jun 21, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $83 → $76 | $41.12 | +84.82% | 4 | May 31, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $26 → $22 | $16.04 | +37.16% | 9 | May 10, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $14 → $13 | $9.80 | +32.65% | 2 | May 10, 2024 | |
| RYTM Rhythm Pharmaceuticals | Downgrades: Neutral | $49 → $42 | $42.67 | -1.57% | 6 | May 8, 2024 | |
| STRO Sutro Biopharma | Initiates: Buy | $12 | $3.05 | +293.44% | 1 | May 8, 2024 | |
| SAGE Sage Therapeutics | Downgrades: Underperform | $24 → $14 | $11.03 | +26.93% | 12 | Apr 17, 2024 | |
| INZY Inozyme Pharma | Maintains: Buy | $16 → $14 | $4.41 | +217.46% | 2 | Apr 9, 2024 | |
| ANNX Annexon | Maintains: Buy | $7 → $10 | $5.05 | +98.02% | 4 | Mar 28, 2024 | |
| FATE Fate Therapeutics | Maintains: Underperform | $2 → $6 | $3.26 | +84.05% | 2 | Mar 28, 2024 | |
| INCY Incyte | Maintains: Neutral | $69 → $67 | $60.87 | +10.07% | 2 | Mar 13, 2024 | |
| OCUL Ocular Therapeutix | Initiates: Buy | $15 | $6.66 | +125.23% | 1 | Feb 9, 2024 | |
| PRTA Prothena Corporation | Downgrades: Neutral | $68 → $38 | $20.48 | +85.55% | 2 | Jan 30, 2024 | |
| ACHL Achilles Therapeutics | Downgrades: Underperform | $7 → $0.5 | $0.80 | -37.66% | 1 | Dec 14, 2023 | |
| PHVS Pharvaris | Maintains: Underperform | $8 → $11 | $18.69 | -41.15% | 2 | Dec 7, 2023 | |
| APLS Apellis Pharmaceuticals | Upgrades: Buy | $52 → $85 | $36.29 | +134.22% | 1 | Dec 5, 2023 | |
| CERE Cerevel Therapeutics Holdings | Downgrades: Neutral | $36 → $31 | $41.35 | -25.03% | 2 | Aug 3, 2023 | |
| BCRX BioCryst Pharmaceuticals | Upgrades: Buy | $10 | $6.67 | +49.93% | 2 | Jul 13, 2023 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $28 → $33 | $21.34 | +54.64% | 2 | Jun 8, 2023 | |
| ADCT ADC Therapeutics | Downgrades: Underperform | $7 → $2 | $3.68 | -45.65% | 2 | Apr 24, 2023 | |
| ASND Ascendis Pharma | Maintains: Buy | $132 → $92 | $133.98 | -31.33% | 5 | Apr 4, 2023 | |
| BNTX BioNTech SE | Maintains: Buy | $239 → $194 | $78.83 | +146.10% | 5 | Mar 28, 2023 | |
| GRTX Galera Therapeutics | Upgrades: Buy | $2 → $7 | $0.13 | +5,500.00% | 2 | Feb 16, 2023 | |
| PRLD Prelude Therapeutics | Downgrades: Underperform | $6 | $3.77 | +59.15% | 4 | Nov 21, 2022 | |
| SRZN Surrozen | Downgrades: Underperform | $75 → $15 | $10.70 | +40.19% | 3 | Nov 17, 2022 | |
| PRAX Praxis Precision Medicines | Downgrades: Neutral | $390 → $60 | $41.19 | +45.67% | 2 | Jun 7, 2022 | |
| PEPG PepGen | Initiates: Buy | $16 | $17.91 | -10.66% | 1 | May 31, 2022 | |
| MTEM Molecular Templates | Downgrades: Underperform | $23 | $1.18 | +1,806.78% | 1 | May 27, 2022 | |
| PYXS Pyxis Oncology | Initiates: Neutral | n/a | $3.20 | - | 1 | Nov 2, 2021 | |
| ARVN Arvinas | Initiates: Buy | n/a | $25.98 | - | 1 | Sep 9, 2021 | |
| ETNB 89bio | Upgrades: Buy | n/a | $7.76 | - | 1 | Sep 25, 2020 | |
| FULC Fulcrum Therapeutics | Downgrades: Underperform | n/a | $6.31 | - | 2 | Aug 12, 2020 | |
| DBVT DBV Technologies | Maintains: Buy | $66 → $60 | $0.82 | +7,229.59% | 1 | Nov 2, 2018 | |
| SPRO Spero Therapeutics | Downgrades: Underperform | n/a | $1.28 | - | 2 | Oct 16, 2018 | |
| PCRX Pacira BioSciences | Maintains: Neutral | n/a | $28.46 | - | 3 | Oct 10, 2018 | |
| PTC PTC Inc. | Maintains: Neutral | n/a | $181.02 | - | 3 | Jun 19, 2018 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | n/a | $140.11 | - | 1 | May 1, 2018 |
Merus
Jun 25, 2024
Maintains: Buy
Price Target: $76
Current: $54.45
Upside: +39.58%
argenx SE
Jun 24, 2024
Reiterates: Buy
Price Target: $535 → $607
Current: $434.22
Upside: +39.79%
PTC Therapeutics
Jun 21, 2024
Maintains: Underperform
Price Target: $25 → $32
Current: $31.17
Upside: +2.66%
Sarepta Therapeutics
Jun 21, 2024
Maintains: Buy
Price Target: $166 → $213
Current: $156.75
Upside: +35.89%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $41.12
Upside: +84.82%
ACADIA Pharmaceuticals
May 10, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $16.04
Upside: +37.16%
Amicus Therapeutics
May 10, 2024
Maintains: Buy
Price Target: $14 → $13
Current: $9.80
Upside: +32.65%
Rhythm Pharmaceuticals
May 8, 2024
Downgrades: Neutral
Price Target: $49 → $42
Current: $42.67
Upside: -1.57%
Sutro Biopharma
May 8, 2024
Initiates: Buy
Price Target: $12
Current: $3.05
Upside: +293.44%
Sage Therapeutics
Apr 17, 2024
Downgrades: Underperform
Price Target: $24 → $14
Current: $11.03
Upside: +26.93%
Inozyme Pharma
Apr 9, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $4.41
Upside: +217.46%
Annexon
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $5.05
Upside: +98.02%
Fate Therapeutics
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $3.26
Upside: +84.05%
Incyte
Mar 13, 2024
Maintains: Neutral
Price Target: $69 → $67
Current: $60.87
Upside: +10.07%
Ocular Therapeutix
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $6.66
Upside: +125.23%
Prothena Corporation
Jan 30, 2024
Downgrades: Neutral
Price Target: $68 → $38
Current: $20.48
Upside: +85.55%
Achilles Therapeutics
Dec 14, 2023
Downgrades: Underperform
Price Target: $7 → $0.5
Current: $0.80
Upside: -37.66%
Pharvaris
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $18.69
Upside: -41.15%
Apellis Pharmaceuticals
Dec 5, 2023
Upgrades: Buy
Price Target: $52 → $85
Current: $36.29
Upside: +134.22%
Cerevel Therapeutics Holdings
Aug 3, 2023
Downgrades: Neutral
Price Target: $36 → $31
Current: $41.35
Upside: -25.03%
BioCryst Pharmaceuticals
Jul 13, 2023
Upgrades: Buy
Price Target: $10
Current: $6.67
Upside: +49.93%
4D Molecular Therapeutics
Jun 8, 2023
Maintains: Buy
Price Target: $28 → $33
Current: $21.34
Upside: +54.64%
ADC Therapeutics
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $3.68
Upside: -45.65%
Ascendis Pharma
Apr 4, 2023
Maintains: Buy
Price Target: $132 → $92
Current: $133.98
Upside: -31.33%
BioNTech SE
Mar 28, 2023
Maintains: Buy
Price Target: $239 → $194
Current: $78.83
Upside: +146.10%
Galera Therapeutics
Feb 16, 2023
Upgrades: Buy
Price Target: $2 → $7
Current: $0.13
Upside: +5,500.00%
Prelude Therapeutics
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $3.77
Upside: +59.15%
Surrozen
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $10.70
Upside: +40.19%
Praxis Precision Medicines
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $41.19
Upside: +45.67%
PepGen
May 31, 2022
Initiates: Buy
Price Target: $16
Current: $17.91
Upside: -10.66%
Molecular Templates
May 27, 2022
Downgrades: Underperform
Price Target: $23
Current: $1.18
Upside: +1,806.78%
Pyxis Oncology
Nov 2, 2021
Initiates: Neutral
Price Target: n/a
Current: $3.20
Upside: -
Arvinas
Sep 9, 2021
Initiates: Buy
Price Target: n/a
Current: $25.98
Upside: -
89bio
Sep 25, 2020
Upgrades: Buy
Price Target: n/a
Current: $7.76
Upside: -
Fulcrum Therapeutics
Aug 12, 2020
Downgrades: Underperform
Price Target: n/a
Current: $6.31
Upside: -
DBV Technologies
Nov 2, 2018
Maintains: Buy
Price Target: $66 → $60
Current: $0.82
Upside: +7,229.59%
Spero Therapeutics
Oct 16, 2018
Downgrades: Underperform
Price Target: n/a
Current: $1.28
Upside: -
Pacira BioSciences
Oct 10, 2018
Maintains: Neutral
Price Target: n/a
Current: $28.46
Upside: -
PTC Inc.
Jun 19, 2018
Maintains: Neutral
Price Target: n/a
Current: $181.02
Upside: -
Neurocrine Biosciences
May 1, 2018
Maintains: Buy
Price Target: n/a
Current: $140.11
Upside: -